Amar Gajjar

Author PubWeight™ 232.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A perivascular niche for brain tumor stem cells. Cancer Cell 2007 11.55
2 Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012 7.61
3 Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2011 6.67
4 Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006 5.96
5 Subtypes of medulloblastoma have distinct developmental origins. Nature 2010 5.94
6 Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005 5.21
7 Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010 4.94
8 Novel mutations target distinct subgroups of medulloblastoma. Nature 2012 4.82
9 Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006 4.72
10 Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2010 4.48
11 Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010 3.70
12 Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004 3.56
13 Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 2011 3.56
14 Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013 3.51
15 Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009 3.32
16 The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A 2009 2.72
17 Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 2004 2.45
18 The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013 2.39
19 Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005 2.34
20 Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol 2012 2.34
21 Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg 2006 2.31
22 Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005 2.19
23 Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 2005 1.93
24 Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009 1.92
25 Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer 2003 1.88
26 Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008 1.87
27 Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol 2014 1.78
28 An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 2011 1.78
29 High-grade astrocytoma in very young children. Pediatr Blood Cancer 2007 1.77
30 ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 2003 1.71
31 Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 2007 1.67
32 Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol 2013 1.66
33 Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 2009 1.57
34 Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014 1.56
35 A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol 2013 1.51
36 Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 2002 1.47
37 Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology 2003 1.45
38 Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol 2012 1.44
39 Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys 2006 1.44
40 Understanding the cognitive impact on children who are treated for medulloblastoma. J Pediatr Psychol 2007 1.42
41 Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005 1.39
42 Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 2011 1.39
43 Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol 2006 1.38
44 Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007 1.35
45 Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 2007 1.34
46 Attention and memory functioning among pediatric patients with medulloblastoma. J Pediatr Psychol 2005 1.31
47 Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer 2010 1.30
48 CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol 2014 1.28
49 Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 2010 1.27
50 Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol 2012 1.25
51 Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol 2010 1.22
52 UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007 1.20
53 Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro Oncol 2012 1.20
54 Atypical white matter volume development in children following craniospinal irradiation. Neuro Oncol 2005 1.20
55 Abnormal hippocampal development in children with medulloblastoma treated with risk-adapted irradiation. AJNR Am J Neuroradiol 2004 1.19
56 Young age may predict a better outcome for children with diffuse pontine glioma. Cancer 2008 1.18
57 A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003 1.17
58 Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol 2012 1.16
59 What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003 1.16
60 Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 2014 1.14
61 Chemotherapy for malignant brain tumors of childhood. J Child Neurol 2008 1.14
62 A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 2008 1.13
63 Decline in corpus callosum volume among pediatric patients with medulloblastoma: longitudinal MR imaging study. AJNR Am J Neuroradiol 2002 1.13
64 Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer 2004 1.13
65 Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol 2013 1.12
66 Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer 2005 1.12
67 Physical performance limitations among adult survivors of childhood brain tumors. Cancer 2010 1.12
68 Early patterns of verbal memory impairment in children treated for medulloblastoma. Neuropsychology 2006 1.11
69 Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010 1.10
70 Survival and functional outcome of children with hypothalamic/chiasmatic tumors. Cancer 2003 1.10
71 Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 2007 1.08
72 Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 2002 1.07
73 Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer 2003 1.06
74 Survival and late mortality in long-term survivors of pediatric CNS tumors. J Clin Oncol 2007 1.05
75 Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 2008 1.05
76 White matter integrity is associated with cognitive processing in patients treated for a posterior fossa brain tumor. Neuro Oncol 2012 1.04
77 Proximal dentatothalamocortical tract involvement in posterior fossa syndrome. Brain 2009 1.03
78 Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 2009 1.02
79 Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004 1.02
80 White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 2004 1.02
81 Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 2002 1.01
82 Current therapy for medulloblastoma. Curr Treat Options Neurol 2006 1.00
83 Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma. Cancer 2006 0.99
84 Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol 2005 0.98
85 Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2013 0.98
86 Chromosome 17 abnormalities in pediatric neuroblastic tumor with abundant neuropil and true rosettes. Am J Clin Pathol 2006 0.97
87 High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 2008 0.97
88 Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer 2006 0.97
89 Diffusion tensor imaging of intraaxial tumors at the cervicomedullary and pontomedullary junctions. Report of two cases. J Neurosurg 2005 0.97
90 Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2013 0.97
91 MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol 2010 0.96
92 Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer 2008 0.95
93 Molecular biology of medulloblastoma: will it ever make a difference to clinical management? J Neurooncol 2005 0.95
94 Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system. Int J Radiat Oncol Biol Phys 2011 0.95
95 Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer 2009 0.93
96 Population pharmacokinetic analysis of topotecan in pediatric cancer patients. Clin Cancer Res 2007 0.93
97 Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012 0.92
98 Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. J Neurooncol 2013 0.91
99 Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer 2006 0.91
100 Successful treatment of early detected trilateral retinoblastoma using standard infant brain tumor therapy. Pediatr Blood Cancer 2010 0.91
101 Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 2003 0.91
102 Differences in brainstem fiber tract response to radiation: a longitudinal diffusion tensor imaging study. Int J Radiat Oncol Biol Phys 2013 0.91
103 Brain tumor therapy-induced changes in normal-appearing brainstem measured with longitudinal diffusion tensor imaging. Int J Radiat Oncol Biol Phys 2011 0.90
104 Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncol 2010 0.89
105 Diffusion tensor imaging of brainstem tumors: axonal degeneration of motor and sensory tracts. J Neurosurg Pediatr 2008 0.88
106 Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res 2013 0.88
107 New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst 2009 0.88
108 A knowledge-guided active contour method of segmentation of cerebella on MR images of pediatric patients with medulloblastoma. J Magn Reson Imaging 2005 0.88
109 Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemother Pharmacol 2005 0.87
110 M1 Medulloblastoma: high risk at any age. J Neurooncol 2008 0.87
111 Diagnostic utility and correlation of tumor markers in the serum and cerebrospinal fluid of children with intracranial germ cell tumors. Childs Nerv Syst 2012 0.86
112 Hemodynamic responses to visual stimulation in children with sickle cell anemia. Brain Imaging Behav 2011 0.86
113 Quantitative morphologic evaluation of white matter in survivors of childhood medulloblastoma. Magn Reson Imaging 2006 0.85
114 Parent-reported social outcomes after treatment for pediatric embryonal tumors: a prospective longitudinal study. J Clin Oncol 2012 0.85
115 Current treatment options for pediatric and adult patients with ependymoma. Curr Treat Options Oncol 2012 0.84
116 Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol 2013 0.84
117 Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. Neuro Oncol 2006 0.84
118 Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol 2012 0.83
119 Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer 2013 0.83
120 Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004 0.82
121 Seizures in children with primary brain tumors: incidence and long-term outcome. Epilepsy Res 2005 0.82
122 Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2003 0.82
123 Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. Clin Cancer Res 2010 0.82
124 High-dose chemotherapy for recurrent medulloblastoma: time for a reappraisal. Cancer 2008 0.82
125 Fanconi anemia and biallelic BRCA2 mutation diagnosed in a young child with an embryonal CNS tumor. Pediatr Blood Cancer 2009 0.82
126 An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol 2015 0.82
127 Regional white matter anisotropy and reading ability in patients treated for pediatric embryonal tumors. Brain Imaging Behav 2010 0.81
128 Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961. Pediatr Blood Cancer 2013 0.81
129 How parents cope with their child's diagnosis and treatment of an embryonal tumor: results of a prospective and longitudinal study. J Neurooncol 2011 0.81
130 Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 2009 0.81
131 Management and outcome of focal low-grade brainstem tumors in pediatric patients: the St. Jude experience. J Neurosurg Pediatr 2013 0.80
132 Isochromosome 17q, MYC amplification and large cell/anaplastic phenotype in a case of medullomyoblastoma with extracranial metastases. Pediatr Blood Cancer 2011 0.80
133 Reirradiation of recurrent medulloblastoma: does clinical benefit outweigh risk for toxicity? Cancer 2014 0.80
134 Characterization, treatment, and outcome of intracranial neoplasms in the first 120 days of life. J Child Neurol 2011 0.80
135 Feasibility and efficacy of a computer-based intervention aimed at preventing reading decoding deficits among children undergoing active treatment for medulloblastoma: results of a randomized trial. J Pediatr Psychol 2013 0.79
136 Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors. Pediatr Blood Cancer 2013 0.79
137 Radiation therapy and adjuvant chemotherapy in a patient with a malignant glioneuronal tumor and underlying ataxia telangiectasia: a case report and review of the literature. J Clin Oncol 2012 0.79
138 Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer Chemother Pharmacol 2005 0.79
139 The use of bone age for bone mineral density interpretation in a cohort of pediatric brain tumor patients. Pediatr Radiol 2008 0.79
140 Central neurogenic hyperventilation and renal tubular acidosis in children with pontine gliomas. Neurology 2014 0.78
141 Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors. Int J Radiat Oncol Biol Phys 2012 0.78
142 Sleep disturbances in adult survivors of childhood brain tumors. Qual Life Res 2012 0.78
143 Molecular characteristics of pediatric high-grade gliomas. CNS Oncol 2014 0.78
144 Radiation therapy quality in CCG/POG intergroup 9961: implications for craniospinal irradiation and the posterior fossa boost in future medulloblastoma trials. Front Oncol 2012 0.77
145 Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer 2013 0.77
146 Dysembryoplastic neuroepithelial tumors and cognitive outcome: cure at a price? Cancer 2010 0.77
147 Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group. Pediatr Blood Cancer 2013 0.77
148 Delayed diagnosis of childhood low-grade glioma: causes, consequences, and potential solutions. Childs Nerv Syst 2015 0.77
149 Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 2015 0.77
150 Restricted access to the environment and quality of life in adult survivors of childhood brain tumors. J Neurooncol 2012 0.76
151 Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma. Pediatr Blood Cancer 2014 0.75
152 Stability of cyclophosphamide in extemporaneous oral suspensions. Ann Pharmacother 2010 0.75
153 Incidental diagnosis of diffuse intrinsic pontine glioma in children. Pediatr Blood Cancer 2015 0.75
154 Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol 2013 0.75
155 Constraint-Induced Movement Therapy for Children With Brain Tumors. Pediatr Phys Ther 2017 0.75
156 Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma. Biomark Res 2013 0.75
157 Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst 2015 0.75
158 Ocular neuromyotonia: video case report. Neurology 2006 0.75
159 896 Anatomic Variants of Ependymoma Arise from Distinct Subsets of Radial Glial Cells. Neurosurgery 2005 0.75
160 Medulloblastoma metastatic to the suprasellar region at diagnosis: a report of six cases with clinicopathologic correlation. Pediatr Neurosurg 2002 0.75